Debio 0123 + Chemotherapy for Small Cell Lung Cancer

Not currently recruiting at 15 trial locations

Overseen By Debiopharm International S.A

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Debiopharm International SA

Must not be taking: Investigational agents

Disqualifiers: Other malignancies, Cardiac issues, Infections, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new treatment, Debio 0123 (experimental treatment), combined with standard chemotherapy drugs, carboplatin and etoposide, for small cell lung cancer (SCLC). The researchers aim to determine the optimal dose of Debio 0123 and assess its safety and tolerability with these chemotherapy drugs. Individuals with SCLC who have experienced a return or worsening of their cancer after previous platinum-based chemotherapy might be suitable candidates for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, you cannot have used an investigational agent or medical device within 28 days before starting the study treatment.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that Debio 0123, when combined with the chemotherapy drugs carboplatin and etoposide, has a manageable safety profile based on early studies. Patients with various solid tumors, including small cell lung cancer, have generally tolerated the treatment well. Some side effects have been reported, but they are usually manageable.

Carboplatin and etoposide are well-known chemotherapy drugs with established safety records. Healthcare providers commonly use them in cancer treatments.

The trial's main goal is to determine the best dose of Debio 0123 and assess its safety when combined with the other drugs. As a Phase 1 trial, the treatment is still under close study for safety, so not all potential risks may be fully known yet. However, previous use of Debio 0123 in similar situations provides some initial confidence in its safety. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for small cell lung cancer?

Unlike the standard treatments for small cell lung cancer, which typically include chemotherapy drugs like etoposide and carboplatin, Debio 0123 introduces a novel approach by acting as a selective inhibitor. This means it specifically targets cancer cells, potentially leading to fewer side effects and improved effectiveness. Researchers are excited about Debio 0123 because it could enhance the effectiveness of traditional chemotherapy agents, offering new hope for patients with this aggressive cancer type. Additionally, the delivery method of Debio 0123, taken orally, offers greater convenience compared to some existing treatment options that require intravenous administration.

What evidence suggests that this trial's treatments could be effective for small cell lung cancer?

Research has shown that Debio 0123, a new drug, may help treat small cell lung cancer. This drug disrupts cancer cell division, hindering their ability to repair DNA damage. In this trial, participants will receive Debio 0123 alongside two chemotherapy drugs, carboplatin and etoposide. Early studies found that Debio 0123 significantly increased the effectiveness of these chemotherapy drugs. This suggests that Debio 0123 could enhance chemotherapy's ability to fight cancer. Although these findings are preliminary, they indicate that this drug could improve outcomes for patients with small cell lung cancer. ^{1 6 7 8 9}

Are You a Good Fit for This Trial?

Adults with small cell lung cancer that's come back or gotten worse after platinum-based therapy can join. They need a confirmed diagnosis, have had prior chemo, be in fairly good health (ECOG 0-1), and expect to live at least 3 more months. They must have measurable disease and not be dealing with major infections like HIV/HBV/HCV, significant heart issues, or other active cancers.

Inclusion Criteria

My tumor is not bleeding.

Life expectancy of at least 3 months in the best judgment of the Investigator

I am fully active or can carry out light work.

Exclusion Criteria

I have a stomach or intestine problem that affects how I absorb pills.

I am not allergic to Debio 0123, etoposide, carboplatin, or their ingredients, or I have successfully undergone desensitization for a carboplatin allergy.

I have or had Hepatitis B, C, or HIV but am cured if previously infected.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

Participants receive Debio 0123 escalating doses, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study

Variable (21-day cycles)

Dose Expansion

Participants receive Debio 0123 at the recommended dose, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study

Variable (21-day cycles)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4-8 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Carboplatin
• Debio 0123
• Etoposide

Trial Overview The trial is testing Debio 0123 combined with carboplatin and etoposide in two parts: first to find the safest dose (RP2D) and then to see how well patients tolerate it. It's for those whose cancer returned or progressed after initial treatment.

How Is the Trial Designed?

Group I: Part 2: Dose Expansion: Debio 0123 + Etoposide + Carboplatin Experimental Treatment 3 Interventions

Participants will receive Debio 0123 recommended dose determined in Part 1 of the study, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study.

Group II: Part 1: Dose Escalation: Debio 0123 + Etoposide + Carboplatin Experimental Treatment 3 Interventions

Participants will receive Debio 0123 escalating doses, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study.

Carboplatin is already approved in United States, European Union, Canada for the following indications:

Approved in United States as Paraplatin for:

• Ovarian cancer
• Testicular cancer
• Lung cancer
• Head and neck cancer
• Brain cancer

Approved in European Union as Carboplatin for:

• Ovarian cancer
• Small cell lung cancer

Approved in Canada as Carboplatin for:

• Ovarian cancer
• Small cell lung cancer
• Testicular cancer

Who Is Running the Clinical Trial?

Debiopharm International SA

Lead Sponsor

Trials

53

Recruited

7,300+

Published Research Related to This Trial

In a phase II trial involving 55 patients with limited-stage small cell lung cancer, the combination of paclitaxel, carboplatin, and etoposide showed promising efficacy, with 37.1% achieving a complete response and 51.4% a partial response.

The treatment was associated with moderate toxicity, primarily hematologic, but no life-threatening complications were reported, indicating that the regimen is tolerable for patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Paclitaxel, carboplatin, and oral etoposide: a phase II trial in limited-stage small cell lung cancer. Gatzemeier, U., Jagos, U., Kaukel, E., et al.[2015]

In a phase III trial involving 317 patients with small cell lung cancer, the carboplatin/etoposide/vincristine (CEV) regimen showed a significantly higher overall response rate of 79.8% compared to 59.8% for the etoposide/vincristine (EV) regimen (P < .001).

While the median survival was slightly longer for CEV-treated patients at 10 months versus 9 months for EV-treated patients, the difference was not statistically significant (P = .19), suggesting that patients with better prognostic factors should receive the more aggressive CEV treatment, while those with poorer factors may benefit from the less intensive EV regimen.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial. Gatzemeier, U., Pawel, JV., Laumen, R., et al.[2015]

In a study of 34 previously untreated patients with extensive small cell lung cancer, a combination of carboplatin and etoposide resulted in an objective response rate of 56%, with 16% achieving a complete response and 41% a partial response.

The treatment was generally well tolerated, with myelosuppression being the main side effect, but there were concerns about potential renal dysfunction and other side effects; however, the efficacy compared to the standard VP-16-cisplatin regimen remains uncertain.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Evans, WK., Eisenhauer, E., Hughes, P., et al.[2019]

Carboplatin/etoposide is an effective treatment for small cell lung cancer, showing results comparable to the traditional cisplatin/etoposide combination, although it has not been directly compared in a randomized study.

This combination has a better safety profile, particularly in elderly patients, and lacks significant nonhematologic side effects, making it suitable for further studies involving dose escalation and bone marrow transplantation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Carboplatin/etoposide in small cell lung cancer. Bishop, JF.[2018]

Carboplatin alone demonstrated a 20% response rate in previously untreated patients with advanced non-small cell lung cancer (NSCLC), indicating its effectiveness as a single-agent treatment.

The combination of carboplatin and etoposide showed a higher response rate of 26.7%, but it also resulted in significantly greater myelosuppressive toxicity, suggesting that while the combination is effective, it may come with increased side effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase II studies with carboplatin in non-small cell lung cancer. Gatzemeier, U., Heckmayr, M., Neuhauss, R., et al.[2018]

In a phase III trial involving 614 patients with small-cell lung cancer, the combination of paclitaxel, etoposide, and carboplatin significantly improved overall survival and progression-free survival compared to the standard treatment of carboplatin, etoposide, and vincristine.

Patients receiving the experimental treatment experienced fewer severe hematologic toxicities, such as anemia and neutropenia, indicating a safer profile for the new combination therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. Reck, M., von Pawel, J., Macha, HN., et al.[2019]

Carboplatin combined with etoposide (CarboEtop) shows a disease control rate of 74.5% in first-line treatment for advanced extra-pulmonary poorly-differentiated neuroendocrine carcinoma, indicating its effectiveness as a treatment option.

The treatment is generally well-tolerated, with myelosuppression being the most common severe side effect (49%), and no significant difference in toxicity between oral and intravenous etoposide, although there was a higher incidence of venous thromboembolism with oral etoposide.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas. Frizziero, M., Spada, F., Lamarca, A., et al.[2020]

A combination treatment of paclitaxel, carboplatin, and oral etoposide was found to be highly effective and well tolerated in 117 patients with small-cell lung cancer, showing promising results in both extensive and limited stages of the disease.

The regimen can be safely administered alongside thoracic radiation therapy, with only a few patients experiencing esophagitis, indicating a favorable safety profile compared to other treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Paclitaxel, carboplatin, and extended-schedule oral etoposide for small-cell lung cancer. Hainsworth, JD., Hopkins, LG., Thomas, M., et al.[2015]

Citations

1. ascopubs.org ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.8098

Debio 0123, a highly selective WEE1 inhibitor, in ... Debio 0123 is an oral, brain-penetrant, highly selective WEE1 inhibitor. WEE1 inhibition leads to S phase and G2/M cell cycle checkpoint abrogation.

2. debiopharm.com debiopharm.com/pipeline/debio-0123

zedoresertib (Debio 0123) Debio 0123 is a Wee1 kinase inhibitor currently in phase I research in refractory solid tumors. The compound is currently in phase I.

3. aacrjournals.org aacrjournals.org/cancerres/article/85/8_Supplement_1/2914/758124/Abstract-2914-The-WEE1-inhibitor-Debio-0123-is

Abstract 2914: The WEE1 inhibitor Debio 0123 is synergistic ... Debio 0123 is a highly selective and brain penetrant WEE1 inhibitor that has previously shown significant preclinical efficacy in ...

4. debiopharm.com debiopharm.com/wp-content/uploads/2022/03/Debio-0123_poster-AACR2022.pdf

the wee1 inhibitor debio 0123 enhances the efficacy of ... The nonclinical data suggest Debio 0123 to be a good candidate for clinical development with the potential to improve therapy outcomes of patients with cancer, ...

5. annalsofoncology.org annalsofoncology.org/article/S0923-7534(24)03423-9/pdf

Clinical trial identification Preclinically, Debio 0123 has shown to significantly improve antitumor activity of CP and ETOP, in SCLC models. These data support clinical investigation of ...

6. annalsofoncology.org annalsofoncology.org/article/S0923-7534(24)03423-9/fulltext

1813TiP Debio 0123, a highly selective WEE1 inhibitor, ... 1813TiP Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin (CP) and etoposide (ETOP) in patients (pts) with small cell lung cancer (SCLC) ...

7. clinicaltrials.gov clinicaltrials.gov/study/NCT05815160

Study Details | NCT05815160 | Debio 0123 in Combination ... The primary purpose of part 2 (dose expansion) of this study is to characterize the safety and tolerability of Debio 0123 at the recommended dose when ...

8. debiopharm.com debiopharm.com/drug-development/publications/debio-0123-a-highly-selective-wee1-inhibitor-combined-with-carboplatin-and-etoposide-in-patients-with-small-cell-lung-cancer-that-progressed-after-platinum-based-therapy-a-phase-1-dose-escalation-a

Debio 0123, a highly selective WEE1 inhibitor, combined ... Debio 0123 is in clinical development, as monotherapy or in combination, in solid tumors, and has shown manageable safety profile with early ...

9. debiopharm.com debiopharm.com/wp-content/uploads/2025/09/Debio-0123-SCLC-104-ASCO-2025.pdf

Debio 0123-SCLC-104 ASCO 2025_Final[88] At data cut off (28 March 2025), 16 patients (mean age of 63.3 years, 7 [43.8%] females) were treated with Debio 0123 at dose levels of 200 mg (N=10), 300 mg (N ...